Merus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics

MT Newswires Live

Dec 02, 2024

Merus (MRUS) has agreed to give Partner Therapeutics an exclusive license to commercialize zenocutuzumab for the potential treatment of NRG1 fusion-positive cancer in the US, the companies said Monday.

Financial details of the licensing agreement weren't disclosed.

Under terms of the agreement, Partner Therapeutics will assume the full rights following a specified transition period.

In exchange, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales.

The US Food and Drug Administration is currently reviewing a Biologics License Application for zenocutuzumab for the treatment of patients with previously treated NRG1 fusion-positive non-small cell lung and pancreatic cancers, the companies added.

Shares of Merus were up around 3% in recent Monday premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2488316671"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2488316671\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2488316671?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-02 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2488316671","market":"fut","top_or_hot":-1,"title":"Merus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics","media":"MT Newswires Live","content":"<html><body><p> Merus (MRUS) has agreed to give Partner <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> an exclusive license to commercialize zenocutuzumab for the potential treatment of NRG1 fusion-positive cancer in the US, the companies said Monday.</p><p>Financial details of the licensing agreement weren't disclosed.</p><p>Under terms of the agreement, Partner Therapeutics will assume the full rights following a specified transition period.</p><p>In exchange, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales.</p><p>The US Food and Drug Administration is currently reviewing a Biologics License Application for zenocutuzumab for the treatment of patients with previously treated NRG1 fusion-positive non-small cell lung and pancreatic cancers, the companies added.</p><p>Shares of Merus were up around 3% in recent Monday premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerus Licenses Potential Lung, Pancreatic Cancer Treatment to Partner Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-12-02 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Merus (MRUS) has agreed to give Partner <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> an exclusive license to commercialize zenocutuzumab for the potential treatment of NRG1 fusion-positive cancer in the US, the companies said Monday.</p><p>Financial details of the licensing agreement weren't disclosed.</p><p>Under terms of the agreement, Partner Therapeutics will assume the full rights following a specified transition period.</p><p>In exchange, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales.</p><p>The US Food and Drug Administration is currently reviewing a Biologics License Application for zenocutuzumab for the treatment of patients with previously treated NRG1 fusion-positive non-small cell lung and pancreatic cancers, the companies added.</p><p>Shares of Merus were up around 3% in recent Monday premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRUS","symbol_name":"Merus B.V.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2488316671","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2488316671","pubTimestamp":1733146972,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Merus  has agreed to give Partner Therapeutics an exclusive license to commercialize zenocutuzumab for the potential treatment of NRG1 fusion-positive cancer in the US, the companies said Monday.Financial details of the licensing agreement weren't disclosed.Under terms of the agreement, Partner Therapeutics will assume the full rights following a specified transition period.In exchange, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales.The US Food and Drug Administration is currently reviewing a Biologics License Application for zenocutuzumab for the treatment of patients with previously treated NRG1 fusion-positive non-small cell lung and pancreatic cancers, the companies added.Shares of Merus were up around 3% in recent Monday premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRUS":"Merus B.V.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4139":"生物科技","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LENZ":"Therapeutics"},"translate_title":"Merus向Partner Therapeutics授予潜在肺癌、胰腺癌治疗许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"MRUS":0.9},"content_text":"Merus (MRUS) has agreed to give Partner Therapeutics an exclusive license to commercialize zenocutuzumab for the potential treatment of NRG1 fusion-positive cancer in the US, the companies said Monday.Financial details of the licensing agreement weren't disclosed.Under terms of the agreement, Partner Therapeutics will assume the full rights following a specified transition period.In exchange, Merus will receive an upfront payment and is eligible to receive milestones and high single-digit to low double-digit royalty payments based on the annual net sales.The US Food and Drug Administration is currently reviewing a Biologics License Application for zenocutuzumab for the treatment of patients with previously treated NRG1 fusion-positive non-small cell lung and pancreatic cancers, the companies added.Shares of Merus were up around 3% in recent Monday premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}